Onclive » Lung Cancer
151 FOLLOWERS
The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non-small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.
Onclive » Lung Cancer
6h ago
Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation ..read more
Onclive » Lung Cancer
6h ago
Paul K. Paik, MD, discusses the FDA approval of tepotinib for metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations ..read more
Onclive » Lung Cancer
6h ago
Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations ..read more
Onclive » Lung Cancer
6h ago
Neel P. Chudgar, MD, discusses considerations for determining lung cancer resection eligibility and how neoadjuvant therapy may affect resectability ..read more
Onclive » Lung Cancer
1w ago
TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer ..read more
Onclive » Lung Cancer
1w ago
The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC ..read more
Onclive » Lung Cancer
1w ago
Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer ..read more
Onclive » Lung Cancer
1w ago
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer ..read more
Onclive » Lung Cancer
3w ago
Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations ..read more
Onclive » Lung Cancer
3w ago
Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC ..read more